- ABEO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Abeona Therapeutics (ABEO) CORRESPCorrespondence with SEC
Filed: 30 Aug 21, 12:00am
Abeona Therapeutics Inc.
1330 Avenue of the Americas, 33rd Floor
New York, NY 10019
August 30, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street NE
Washington, DC 20549
Attention: Chris Edwards
Re: | Abeona Therapeutics Inc. | |
Registration Statement on Form S-3 | ||
Filed on June 7, 2021 | ||
File No. 333-256850 |
Dear Mr. Edwards:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on August 27, 2021, in which we requested the acceleration of the effectiveness of the above-captioned Registration Statement to 4:00 p.m., Eastern time, on August 31, 2021, or as soon as practicable thereafter. We hereby formally withdraw our prior request for acceleration of the effective date of the above-captioned Registration Statement.
Thank you for your attention to this matter.
Very truly yours, | ||
Abeona Therapeutics Inc. | ||
By: | /s/ Edward Carr | |
Name: | Edward Carr | |
Title: | Chief Financial Officer |
cc: | John J. Concannon III, Morgan, Lewis & Bockius LLP |